Premium
Maternal plasma prostaglandin E 2 metabolite levels during human pregnancy and parturition
Author(s) -
BRENNECKE S. P.,
CASTLE B. M.,
DEMERS L. M.,
TURNBULL A. C.
Publication year - 1985
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1985.tb01107.x
Subject(s) - metabolite , radioimmunoassay , prostaglandin , prostaglandin f , gestation , prostaglandin e , pregnancy , endocrinology , dinoprostone , medicine , chemistry , endogeny , biology , genetics
Summary. Because of methodological problems associated with the measurement in biological fluids of both prostaglandin E 2 (PGE 2 ) and its unstable principal circulating metabolite 13,14‐dihydro‐15‐keto‐PGE 2 (PGEM), there is little reliable information on these prostaglandins in human pregnancy and parturition. The recent discovery of a stable PGEM degradation product 11‐deoxy‐13,14‐dihydro‐15‐keto‐11β, 16‐cyclo‐PGE 2 (bicyclo‐PGEM) has provided a means of studying endogenous plasma levels of PGEM which circumvents the problems encountered with direct measurements of PGE 2 and PGEM. Using a radioimmunoassay for bicyclo‐PGEM we have therefore determined maternal peripheral plasma PGE 2 metabolite levels during human gestation. PGE 2 metabolite levels did not alter significantly during the second or third trimesters nor during labour. This contrasts with maternal peripheral plasma levels of the principal circulating metabolite of PGF 2α 13,14‐dihydro‐15‐keto‐PGF 2α (PGFM) which increases several fold during labour. Compared t o PGE 2 therefore. PGF 2α may be quantitatively the more significant prostaglandin associated with human parturition.